StreetInsider.com News Articles

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the Company's common shares have been approved for listing on Nasdaq. NervGen’s common shares will begin trading on Nasdaq today, under the symbol “NGEN.”

"A listing on Nasdaq marks a defining moment in NervGen’s evolution as a leading biopharmaceutical company developing neuroreparative therapeutics," said Adam Rogers, MD, Interim Chief Executive Officer of NervGen Pharma. "With

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Begins Trading on Nasdaq Today

Thu, 08 Jan 2026 06:30:00 -0500

NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Wed, 17 Dec 2025 16:19:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has filed a registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.

The Registration Statement filed with the SEC has not yet become effective. No Securities may be sold, nor may offers to buy be accepted,

NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Wed, 17 Dec 2025 16:19:00 -0500

The Registration Statement filed with the SEC has not yet become effective. No Securities may be sold, nor may offers to buy be accepted,

NervGen Pharma Announces Proposed Amendment to Warrants

Fri, 12 Dec 2025 19:51:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Company intends to amend 5,075,000 common share purchase warrants (the "2022 Warrants") that were issued pursuant to a private placement of units that closed on July 13, 2022. The proposed amendment solely changes the denomination of the exercise price of the 2022 Warrants from US$1.75 to the Canadian equivalent of C$2.44 to align with the Company's functional